Targeted PLGA Nanoparticles for the Sustained Release of Hypertensive Drugs

Abstract

The focus of this study was to create a PLGA-PEG copolymer nanoparticle (NP), encapsulating the anti-hypertensive drugs valsartan and captopril. The surface of the NP was modified with an anti-ICAM antibody to allow for targeted cell adhesion. DLS data determined the size of the NPs to be between 120 and 150 nm, and the zeta potential had a minimum value of -27 mV. SEM images of the NPs showed smooth spherical morphology consist with all NP formation types. The PEG modification and ICAM antibody conjugation were found successful, and the drug encapsulated NP show a sustained release of both drugs for almost four days. The ICAM NPs were able to specifically bind to the ICAM receptors on the surface of TNF alpha activated Human Endothelial Cells (HUVECs) in static conditions. A flow chamber was designed and constructed to test the capacity of the ICAM NP ability to bind under flow. Initial results demonstrated the possible binding of the NPs under 15 dynes/cm2 shear stress.